Every FDE engagement that has stalled on the named operator side has stalled on the same line item in the Readiness List — the difference between a named owner and a named sponsor. Neither is wrong. The naming is precise, and the engagement stalls when the readiness list confuses one for the other.
A named sponsor is the person with authority to sign things off. They are usually a CIO, CMIO, or VP of Customer Success. They have the title, the budget, and the political cover to defend the deployment to their board. They will speak at the steering committee, they will write the budget memo, they will be quoted in the press release when this is over.
A named sponsor is not the person who closes readiness cells.
A named owner is the person who closes readiness cells. They might not have authority. They might be a clinical informatics lead, a frontline nurse manager, an integration architect, or a pharmacy operations supervisor. They are the people whose actual day-to-day work contains the workflows the deployment will land on. They will not speak at the steering committee. They will not be quoted in the press release. They will, however, decide whether the engagement holds at week six.
The Rules of Engagement settles the distinction on day one. The intake asks for names. The names are not titles, and they are not sponsors. When the intake is filled and the named sponsors are not the people being asked to close readiness cells, we open a conversation about who is — before we agree to staff. When the intake is filled with titles or sponsors instead of names, we return the intake with the column heading rewritten.
A successful healthcare technology engagement is not the one with the strongest sponsor. It is the one with the most accurate Readiness List — the cell-by-cell ledger of named owners the engagement has to close at the named cadence. The sponsor covers the engagement from above. The named owners close it from the floor. The engagement closes on whichever set of names is the truth.